Lastly, given that LRRTM2 is a protein involved in synaptic formation, it suggests that SGLT2 inhibitors may have a certain regulatory effect on neurological diseases, thereby broadening the clinical application of SGLT2 inhibitors. Here, LRRTM2 is linked to nervous system disorder.